4. Progression‐free survival (PFS) for platinum combination versus non‐platinum therapy.

Author, year	n (elderly)	Median PFS (95% CI)		HR (95% CI)	P value
		Non‐platinum single agent	Platinum‐based combination
Quoix 2011b	451	2.8 (2.6‐3.7) months	6.0 (5.5‐6.8) months	0.51 (0.42‐0.62)	< 0.0001
Abe 2011	233	4.4 (3.4‐5.1) months	4.7 (4.1‐5.8) months	0.92 (0.71‐1.20)	0.55
Chen 2008	65	3.1 (NR) months	5.2 (NR) months	0.66 (0.42‐1.04)	0.07
Georgoulias 2004	70	2.5 (NR) months	4.3 months	0.86 (0.58‐1.29)	0.48
Boni 2012	101	NR	NR	0.61 (0.40‐0.93)	0.02
Kubota 2008	118	5.8 (MR) months	5.8 (NR) months	0.90 (0.62‐1.31)	0.58
Georgoulias 2005	82	4.5 (NR) months	4.6 (NR) months	1.10 (0.70‐1.73)	0.68
Laack 2004	43	10.9 (3.4‐24.9) weeks	17.1 (8.4‐32.4) weeks	0.71 (0.35‐1.44)	0.34
Georgoulias 2001	71	2.5 (NR) months	5.1 (NR)	0.81 (0.50‐1.31)	0.39

95% CI: 95% confidence interval; HR: hazard ratio; NR: not reported; PFS: progression‐free survival.